Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis.

Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, Fritz P, Schwab M, Schaeffeler E.

Clin Pharmacol Ther. 2011 Mar;89(3):422-8. doi: 10.1038/clpt.2010.348. Epub 2011 Feb 2.

PMID:
21289623
2.

Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus.

Hirai F, Takatsu N, Yano Y, Satou Y, Takahashi H, Ishikawa S, Tsurumi K, Hisabe T, Matsui T.

J Gastroenterol Hepatol. 2014 Jan;29(1):60-6. doi: 10.1111/jgh.12361.

PMID:
24033383
3.

Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.

Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK.

Transplantation. 2009 Apr 27;87(8):1225-31. doi: 10.1097/TP.0b013e31819f117e.

PMID:
19384171
4.

Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.

Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.

Transplant Proc. 2012 Jan;44(1):109-14. doi: 10.1016/j.transproceed.2011.11.004.

PMID:
22310591
5.

Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.

Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK.

J Clin Pharm Ther. 2011 Oct;36(5):614-24. doi: 10.1111/j.1365-2710.2010.01206.x. Epub 2010 Oct 5.

PMID:
21916909
6.

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.

Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N.

Int J Mol Med. 2011 Dec;28(6):1093-102. doi: 10.3892/ijmm.2011.794. Epub 2011 Sep 12.

PMID:
21922127
7.

Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.

Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A.

Pharmacol Rep. 2010 Nov-Dec;62(6):1159-69.

8.

CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).

Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, Yoon YR, Won DI, Kim CD.

Transplantation. 2013 Mar 27;95(6):828-34. doi: 10.1097/TP.0b013e31827eef57.

PMID:
23364483
9.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000. Review.

PMID:
20170205
10.

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.

Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.

Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.

PMID:
17635182
11.

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.

Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.

Basic Clin Pharmacol Toxicol. 2008 Dec;103(6):546-52. doi: 10.1111/j.1742-7843.2008.00327.x.

12.

Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.

Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Aug;380(2):169-77. doi: 10.1007/s00210-009-0415-y. Epub 2009 Apr 3.

PMID:
19343327
13.

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.

Rahsaz M, Azarpira N, Nikeghbalian S, Aghdaie MH, Geramizadeh B, Moini M, Banihashemi M, Darai M, Malekpour Z, Malekhosseini SA.

Exp Clin Transplant. 2012 Feb;10(1):24-9.

14.

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.

Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.

Pharmacogenomics. 2011 Sep;12(9):1293-303. doi: 10.2217/pgs.11.70. Epub 2011 Aug 1.

PMID:
21806386
15.

Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?

Singh R, Srivastava A, Kapoor R, Mittal RD.

J Clin Pharmacol. 2011 Apr;51(4):603-15. doi: 10.1177/0091270010370704. Epub 2010 Jun 22.

PMID:
20571034
16.

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.

Clin Chem. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.

17.

CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.

Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C.

Nephrol Dial Transplant. 2011 Sep;26(9):3046-50. doi: 10.1093/ndt/gfr253. Epub 2011 Jun 15.

PMID:
21677300
18.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Apr;49(4):207-21. doi: 10.2165/11317550-000000000-00000. Review.

PMID:
20214406
19.

Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.

Díaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E.

Transplant Proc. 2012 Nov;44(9):2635-8. doi: 10.1016/j.transproceed.2012.09.062.

PMID:
23146479
20.

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.

Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.

Clin Pharmacol Ther. 2007 Dec;82(6):711-25. Epub 2007 May 9.

PMID:
17495880

Supplemental Content

Support Center